RELY vs. KNSA
RELY (Remitly Global, Inc.) and KNSA (Kiniksa Pharmaceuticals, Ltd.) are both stocks. RELY operates in Software - Infrastructure (Technology), while KNSA operates in Biotechnology (Healthcare). Over the past 3 years, RELY returned 5.00%/yr vs 57.85%/yr for KNSA. Their 0.24 correlation means their historical movements had little consistent relationship.
Performance
RELY vs. KNSA - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, RELY achieves a 65.00% return, which is significantly lower than KNSA's 80.22% return.
RELY
- 1D
- -2.90%
- 1M
- -0.78%
- 6M
- 72.24%
- YTD
- 65.00%
- 1Y
- 38.00%
- 3Y*
- 5.00%
- 5Y*
- —
- 10Y*
- —
- ALL TIME*
- -15.95%
KNSA
- 1D
- -4.94%
- 1M
- 18.22%
- 6M
- 69.26%
- YTD
- 80.22%
- 1Y
- 145.67%
- 3Y*
- 57.85%
- 5Y*
- 37.13%
- 10Y*
- —
- ALL TIME*
- 14.55%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
| $68.75M | $54.52M | $46.86M | |
| $53.79M | $61.54M | $101.04M |
RELY vs. KNSA - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
RELY Remitly Global, Inc. | 65.00% | -38.86% | 16.22% | 69.61% | -44.47% | -61.02% |
KNSA Kiniksa Pharmaceuticals, Ltd. | 80.22% | 108.54% | 12.77% | 17.09% | 27.27% | 1.38% |
Correlation
The correlation between RELY and KNSA is 0.21, which is low. Their historical price movements had little consistent relationship.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.21 |
Correlation (3Y) Balances recent behavior with more history. | 0.20 |
Correlation (All Time) Calculated using the full available price history since Sep 23, 2021 | 0.24 |
Fundamentals
RELY:
$4.79B
KNSA:
$5.67B
RELY:
$0.49
KNSA:
$1.00
RELY:
46.69
KNSA:
74.38
RELY:
0.25
KNSA:
0.72
RELY:
2.86
KNSA:
7.14
RELY:
5.45
KNSA:
9.48
RELY:
$1.73B
KNSA:
$840.85M
RELY:
$753.03M
KNSA:
$546.22M
RELY:
$142.85M
KNSA:
$111.62M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
RELY vs. KNSA — Risk / Return Rank
RELY
KNSA
RELY vs. KNSA - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Remitly Global, Inc. (RELY) and Kiniksa Pharmaceuticals, Ltd. (KNSA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| RELY | KNSA | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.26 | ||
| Sortino ratioReturn per unit of downside risk | -2.90 | ||
| Omega ratioGain probability vs. loss probability | 1.19 | 1.52 | -0.33 |
| Calmar ratioReturn relative to maximum drawdown | 0.96 | 6.94 | -5.98 |
| Martin ratioReturn relative to average drawdown | 1.76 | 24.13 | -22.37 |
Loading charts...
Drawdowns
RELY vs. KNSA - Drawdown Comparison
The maximum RELY drawdown since its inception was -86.99%, roughly equal to the maximum KNSA drawdown of -83.06%. Use the drawdown chart below to compare losses from any high point for RELY and KNSA.
Loading charts...
Drawdown Indicators
| RELY | KNSA | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -86.99% | -83.06% | -3.93% |
Max Drawdown (1Y)Largest decline over 1 year | -39.75% | -21.12% | -18.63% |
Max Drawdown (3Y)Largest decline over 3 years | -57.92% | -34.14% | -23.78% |
Max Drawdown (5Y)Largest decline over 5 years | — | -53.17% | — |
Current DrawdownCurrent decline from peak | -56.96% | -8.13% | -48.83% |
Average DrawdownAverage peak-to-trough decline | -67.14% | -40.09% | -27.05% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 21.71% | 6.06% | +15.65% |
Volatility
RELY vs. KNSA - Volatility Comparison
The current volatility for Remitly Global, Inc. (RELY) is 11.62%, while Kiniksa Pharmaceuticals, Ltd. (KNSA) has a volatility of 26.47%. This indicates that RELY experiences smaller price fluctuations and is considered to be less risky than KNSA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| RELY | KNSA | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 11.62% | 26.47% | -14.85% |
Volatility (6M)Calculated over the trailing 6-month period | 38.88% | 41.55% | -2.67% |
Volatility (1Y)Calculated over the trailing 1-year period | 56.25% | 49.77% | +6.48% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 58.70% | 54.77% | +3.93% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 58.70% | 64.34% | -5.64% |
Dividends
RELY vs. KNSA - Dividend Comparison
Neither RELY nor KNSA has paid dividends to shareholders.
Financials
RELY vs. KNSA - Financials Comparison
This section allows you to compare key financial metrics between Remitly Global, Inc. and Kiniksa Pharmaceuticals, Ltd.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
RELY vs. KNSA - Profitability Comparison
RELY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Remitly Global, Inc. reported a gross profit of 0.00 and revenue of 452.80M. Therefore, the gross margin over that period was 0.0%.
KNSA - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Kiniksa Pharmaceuticals, Ltd. reported a gross profit of 220.03M and revenue of 243.60M. Therefore, the gross margin over that period was 90.3%.
RELY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Remitly Global, Inc. reported an operating income of 53.74M and revenue of 452.80M, resulting in an operating margin of 11.9%.
KNSA - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Kiniksa Pharmaceuticals, Ltd. reported an operating income of 27.19M and revenue of 243.60M, resulting in an operating margin of 11.2%.
RELY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Remitly Global, Inc. reported a net income of 49.05M and revenue of 452.80M, resulting in a net margin of 10.8%.
KNSA - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Kiniksa Pharmaceuticals, Ltd. reported a net income of 25.43M and revenue of 243.60M, resulting in a net margin of 10.4%.
Frequently Asked Questions
RELY and KNSA have a correlation of 0.21, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
KNSA has higher volatility (26.47%) compared to RELY (11.62%). In terms of maximum drawdown, RELY dropped -86.99% vs KNSA's -83.06%.
KNSA currently has the higher Sharpe Ratio (2.94 vs 0.68), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for RELY and KNSA
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer